FDA Finalizes Guidance to Expand Cancer Clinical Trial Eligibility

The U.S. Food and Drug Administration has finalized guidance to broaden eligibility criteria for cancer clinical trials. This update aims to increase patient access to research by loosening restrictions on factors like performance status, concomitant medications, and laboratory values. This could allow more individuals to participate in potentially life-saving studies.